LONDON — Building up its base of medicines for lung diseases, GSK said Wednesday it was buying the privately held firm 35Pharma for $950 million in cash.
The centerpiece of the deal is an experimental drug called HS235 that is set to start trials in pulmonary arterial hypertension, a form of high blood pressure in the lungs.
The disease has increasingly become a target for drugmakers in recent years. Merck’s Winrevair won approval for PAH in 2024, and reached $1.4 billion in sales last year.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
